# Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

> **NCT05210413** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University Hospital, Bordeaux** · enrollment: 80 (actual)

## Conditions studied

- Refractory or Recurrent Solid Tumor

## Interventions

- **DRUG:** Spartalizumab in Pediatric cohort
- **DRUG:** Low-dose Pazopanib in Pediatric Cohort
- **DRUG:** Spartalizumab in Adult cohort
- **DRUG:** Low-dose Pazopanib in Adult Cohort

## Key facts

- **NCT ID:** NCT05210413
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-17
- **Primary completion:** 2025-08-26
- **Final completion:** 2027-11-17
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05210413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05210413, "Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05210413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*